Cell and Immune Therapeutics for Gliomas
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Microenvironment".
Deadline for manuscript submissions: 10 August 2024 | Viewed by 853
Special Issue Editors
Interests: diffuse midline glioma; glioblastoma; drug delivery; immunotherapy
Interests: angiogenesis; neuro-oncology; translational drug discovery; personalized medicine; genomics; biomarkers; experimental therapeutics; brain mapping; health outcomes; brain metastases; clinical guideline
Special Issue Information
Dear Colleagues,
High-grade gliomas in adults and children, such as glioblastoma multiforme and diffuse intrinsic pontine glioma/diffuse midline glioma, are highly fatal tumours for which there are no curative options. Despite the development of intensive therapies such as radio-chemotherapy and targeted drug approaches, survival has not improved, with most patients dying within the first year after diagnosis. The heterogeneous nature of these tumours makes them resistant to multiple anticancer agents, resulting in limited treatment. These tumors also evade the immune system via the abundant presence of a highly tumour-promoting and immunosuppressive tumour immune microenvironment. Cell therapy is a conceptually attractive treatment option for adult and paediatric gliomas.
Strategies to modulate the immune microenvironment in gliomas to help myeloid cells increase antitumour effector functions and promote a robust therapeutic response, ranging from small molecules to monoclonal antibodies, include the use of immune checkpoint inhibitors, CAR T and NK cells, gamma-delta T cells, oncolytic viruses, macrophages, dendritic cells and microglia. Stem cell-based approaches in which neural and mesenchymal stem cells are promoted to home in on the tumour and deliver therapeutic cargo to facilitate a multifaceted anti-tumour immune response to glioma tissue also show promise.
The current Special Issue will accept basic biology and translational submissions, including original research, reviews, short communications, and methodological articles in glioma treatment focusing on immune cell- and stem cell-derived adoptive cell therapies, animal disease models, and cellular/molecular mechanisms.
Dr. John I. Bianco
Prof. Dr. Steven Brem
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immune modulation
- T-cell activation
- tumour-associated macrophages
- tumour microenvironment
- stem cells
